The government has allocated a budget of Rs 9.5 crore, underscoring its dedication to fostering a robust ecosystem for pharmaceutical innovation and testing

In a groundbreaking move, the Uttar Pradesh government has introduced its inaugural Standard Operating Procedures (SOPs) aimed at transforming pharmaceutical manufacturing and clinical research within the state. This strategic initiative is set to position Uttar Pradesh as a formidable contender in the global pharmaceutical arena.

Central to this endeavour, 20 leading medical institutions across the state have been enlisted to conduct clinical trials. These institutions will adhere to internationally recognised protocols and undergo specialised training to uphold the highest standards in clinical research. To support this, the government has allocated a budget of Rs 9.5 crore, underscoring its dedication to fostering a robust ecosystem for pharmaceutical innovation and testing.

The comprehensive strategy encompasses organizing conferences with regional experts and medical education institutions to address industry challenges and opportunities. Additionally, it involves developing standardized resources for certified pharmaceutical counselling, harmonising industry practices, and providing training on clinical trials and Good Clinical Practices for doctors and researchers in 20 medical colleges. Furthermore, the initiative aims to establish strategic Memorandums of Understanding (MoUs) with esteemed institutions such as the Translational Health Science and Technology Institute (THSTI), Dr APJ Abdul Kalam Technical University (AKTU), and the Biotechnology Industry Research Assistance Council (BIRAC).

This initiative is poised to fortify Uttar Pradesh's pharmaceutical sector, generate employment opportunities, and amplify the state's influence in both national and international healthcare economies. Complementing this, the state's Pharmaceutical Industry Policy offers substantial incentives, including a 75 per cent reimbursement of the total expenditure incurred on clinical trials, up to a maximum of Rs 1 crore per trial, for research and development institutes situated within Uttar Pradesh.

By implementing these SOPs and fostering collaborations with premier institutions, Uttar Pradesh is charting a course toward becoming a pivotal hub for pharmaceutical manufacturing and clinical research in the country.